MULTIPLE MYELOMA

This study aimed to see if a stem cell transplant from a donor could cure multiple myeloma after it returns following initial treatment. It compared this intensive, one-time procedure to ongoing conventional drug therapy. The trial was for patients whose cancer had relapsed and w…

This study tested a new oral drug, CC-92480, given alone and with a steroid (dexamethasone), for adults with multiple myeloma that has come back and stopped responding to many standard treatments. The main goals were to find a safe dose and see if the drug combination could shrin…

This early-stage study tested the safety and initial effectiveness of a new drug, modakafusp alfa, when given alongside an existing drug, daratumumab, for people with multiple myeloma that has returned or stopped responding to other treatments. The main goal was to find a safe do…

This early-stage trial tested whether combining a personalized immune cell therapy (called bb2121 or ide-cel) with other drugs could help adults with multiple myeloma that had returned or stopped responding to standard treatments. The study aimed to find safe doses and see if the…

This early-stage study aimed to find the safest dose of a drug called tasquinimod for people with multiple myeloma that has come back or stopped responding to treatment. Researchers tested tasquinimod by itself and combined with a standard three-drug regimen. The main goal was to…

This study tested whether adding the drug bortezomib to a standard high-dose chemotherapy regimen before a stem cell transplant would help older adults with multiple myeloma live longer without their cancer getting worse. It involved 63 patients aged 60 and older and directly com…

This early-phase study aimed to see if a drug called belantamab mafodotin (Blenrep) could help prevent multiple myeloma from returning in patients who had already relapsed and received a salvage stem cell transplant. Researchers wanted to test the safety of giving this drug as on…

This early-phase study tested a new drug called INCB000928 to see if it could safely treat anemia (low red blood cells) in people with myelodysplastic syndromes (MDS) or multiple myeloma. The main goals were to find a safe dose and see if the drug could reduce the need for blood …

This study tested an experimental cell therapy called PHE885 for adults with multiple myeloma that has returned or stopped responding to multiple standard treatments. Researchers collected immune cells from participants, genetically modified them to target cancer cells, and reinf…

This study tested a new drug called modakafusp alfa for people with multiple myeloma, a type of blood cancer, that had returned or stopped responding to at least three prior treatments. The main goals were to find a safe and effective dose and to see if the drug could help contro…

This study tested an experimental immune therapy called CAR-T cells in Chinese patients with multiple myeloma that had returned or stopped responding to standard treatments. Researchers collected and reprogrammed patients' own immune cells to attack cancer cells, then infused the…

This early-stage study aimed to find a safe dose and check for side effects of a new drug, modakafusp alfa, when given with other approved myeloma medications. It involved adults with multiple myeloma, including those newly diagnosed after a stem cell transplant and those whose c…

This study tested a special training program designed to help people who have lost their sense of taste or smell after chemotherapy for blood cancers. It aimed to see if this 'sensory rehab' could improve their ability to taste and smell, which would help them eat better and feel…

This study aimed to understand how certain chemicals in the blood and urine, which indicate bone health, change over time in older patients with multiple myeloma. The patients were receiving a standard intravenous medication to strengthen their bones. The study was terminated ear…

This study aims to understand why some multiple myeloma patients experience shortness of breath when taking the cancer drug carfilzomib. Researchers will use a special device to measure blood vessel health in 50 patients receiving this treatment. The goal is to identify risk fact…